The DOI matches its Crossref record; 11 of the 13 references it cites were found in a registry or an index.
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Open accessAbstract
Background Patients with HER2-positive early breast cancer (EBC) preferred subcutaneous (s.c.) trastuzumab, delivered via single-use injection device (SID), over the intravenous (i.v.) formulation (Cohort 1 of the PrefHer study: NCT01401166). Here, we report patient preference, healthcare professional satisfaction, and safety data pooled from Cohort 1 and also Cohort 2, where s.c. trastuzumab was delivered via hand-held syringe.Patients and methods Patients were randomized to receive four adjuvant cycles of 600 mg fixed-dose s.c. trastuzumab followed by four cycles of standard i.v. trastuzumab, or vice versa. The primary endpoint was overall preference proportions for s.c. or i.v., assessed by patient interviews in the evaluable ITT population.Results A total of 245 patients were randomized to receive s.c. followed by i.v. and 243 received i.v. followed by s.c. (evaluable ITT populations: 235 and 232 patients, respectively). s.c. was preferred by 415/467 [88.9%; 95% confidence interval (CI) 85.7-91.6; P < 0.0001; two-sided test against null hypothesis of 65% s.c. preference]; 45/467 preferred i.v. (9.6%; 95% CI 7-13); 7/467 indicated no preference (1.5%; 95% CI 1-3). Clinician-reported adverse events occurred in 292/479 (61.0%) and 245/478 (51.3%) patients during the pooled s.c. and i.v. periods, respectively (P < 0.05; 2 × 2 χ(2)); 16 patients (3.3%) in each period experienced grade 3 events; none were grade 4/5.Conclusions PrefHer revealed compelling and consistent patient preferences for s.c. over i.v. trastuzumab, regardless of SID or hand-held syringe delivery. s.c. was well tolerated and safety was consistent with previous reports, including the HannaH study (NCT00950300). No new safety signals were identified compared with the known i.v. profile in EBC. PrefHer and HannaH confirm that s.c. trastuzumab is a validated and preferred option over i.v. for improving patients' care in HER2-positive breast cancer.Clinicaltrialsgov registration number NCT01401166.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PrefHer study (NCT01401166), in which patients with EBC were randomized to receive four cycles of SC trastuzumab followed by four cycles of IV trastuzumab, or vice versa, demonstrated a strong patient preference and increased HCP satisfaction with SC over IV administration [39, 40].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [40]
In the citing paper
“After subcutaneous formulations of trastuzumab and rituximab were introduced in Europe in 2013 and 2014, respectively, it became evident that a change from intravenous infusions to subcutaneous bolus injections in oncology not only reduced the drug administration burden on the healthcare system but was also generally preferred by patients and HCPs [5–8].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [5]
In the citing paper
“The subcutaneous dosing alternative presents a number of advantages over intravenous dosing, including hospital and clinical cost savings, reduced time and resource use, increased flexibility in appointment scheduling, and reduced capacity bottlenecks and nursing overtime [5, 37, 38].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [5]
In the citing paper
“In the international PrefHer study, 415/467 patients preferred subcutaneous over intravenous dosing (88.9%; 95% CI 85.7–91.6; p < 0.0001; two-sided test against null hypothesis of 65% subcutaneous preference); 45/467 preferred intravenous (9.6%; 95% CI 7–13); and 7/467 indicated no preference (1.5%; 95% CI 1–3) [5].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [5]
In the citing paper
“After subcutaneous formulations of trastuzumab and rituximab were introduced in Europe in 2013 and 2014, respectively, it became evident that a change from intravenous infusions to subcutaneous bolus injections in oncology not only reduced the drug administration burden on the healthcare system but was also generally preferred by patients and HCPs [5–8].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [5]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-5-678_2 · Cited by 1,471
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F., Poortmans, P., Thompson, A., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351 · cited 4×
“groups, respectively) in the phase III HannaH study (NCT00950300) [4].”
BackgroundInfluentialSelf-citationPivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230
Self-citationBurcombe, R., Chan, S., Simcock, R., Samanta, K., Percival, F., & Barrett-Lee, P. (2013) · Advances in Breast Cancer Research · doi:10.4236/abcr.2013.24022 · Cited by 59
Self-citationWynne, C., Ellis-Pegler, R. B., Waaka, D., Schwabe, C., Lehle, M., Heinzmann, D., Mangat, R., Li, C., Dick, A. E., Cranshaw, N. A., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2273-z · Cited by 25
Pivot, X. B., Gligorov, J., Müller, V., Verma, S., Knoop, A. S., Curigliano, G., Camcı, C., Jenkins, V. A., Scotto, N., Osborne, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-p4-12-11 · Cited by 10
Self-citationHegg, R., Pienkowski, T., Chen, S., Staroslawska, E., Falcon, S., Kovalenko, N., Al-Sakaff, N., Heinzmann, D., Kolaitis, G., & Ismael, G. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32835-0 · Cited by 9
Research works printed but not linked: 6
- National Comprehensive Cancer Network, 2014, NCCN Clinical Practice Guidelines in Oncology: Breast Cancer
- De Cock, 2013, Manual injection of subcutaneous trastuzumab vs intravenous infusion for HER2-positive early breast cancer: a time-and-motion study., Eur J Cancer, 49, S432
- ICH Harmonised Tripartite Guideline, 1995, Clinical safety data management: definitions and standards for expedited reporting E2A
- Fallowfield, 2013, Reasons for patients’ preferences for subcutaneous or intravenous trastuzumab in the PrefHer study, Eur J Cancer, 49, S385
- Gligorov J, Curigliano G, Müller V et al. Assessment of adverse events in patients switching between trastuzumab administration routes (subcutaneous to intravenous and intravenous to subcutaneous) in the PrefHer study. In: 9th European Breast Cancer Conference, Glasgow, Scotland, 2014. Abstract 229.
- De Cock E, Pan I, Sandoval M et al. Healthcare professionals’ perceptions of the impact on clinical management of switching from the intravenous to the subcutaneous formulation of trastuzumab. In: 9th European Breast Cancer Conference, Glasgow, Scotland, 2014. Abstract 42.
Cited by
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447
Zhou, Q., Jin, J.-F., Zhu, L.-L., Chen, M., Xu, H.-M., Wang, H.-F., Feng, X.-Q., & Zhu, X.-P. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s87271 · Cited by 296
Trastuzumab in the Treatment of Breast Cancer
Maximiano, S., Magalhães, P., Guerreiro, M. P., & Morgado, M. (2016) · BioDrugs · doi:10.1007/s40259-016-0162-9 · Cited by 223
Tan, A. R., Im, S.-A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., De Laurentiis, M., Pierga, J.-Y., Jung, K. H., Schem, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30536-2 · Cited by 177
Metadata
- Authors
- Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., Fallowfield, L., Jenkins, V., Kilkerr, J., Langridge, C., Monson, K., Jakobsen, E. H., Nielsen, M. H., Linnet, S., Knoop, A., Pivot, X., Bonnefoi, H., Mousseau, M., Zelek, L., Bourgeois, H., Lefeuvre, C. P., Bachelot, T., Petit, T., Brain, E., Levy, C., Gligorov, J., Augustin, D., Graf, H., Heinrich, G., Kroening, H., Kuemmel, S., Müller, V., Overkamp, F., Park-Simon, T.-W., Schmidt, M., Perlova-Griff, L., Wolf, C., Colleoni, M., Ballestrero, A., Bernardo, A., Ribecco, A. S., Gianni, L., Curigliano, G., Brewczynska, E., Jassem, J., Shirinkin, V., Manikhas, A., Dvornichenko, V., Lichinitser, M., Semiglazov, V., Mukhametshina, G., Bulavina, I., Arranz, E. E., Ocon, F. C., Vivanco, G. L., Bofill, J. S., Quintela, I. P., Muñoz, A. S., Pérez, Y. F., Espinosa, J. C., Alvarez, J. V., del Prado, R. L., De Merino, L. C., García, J. M. P., Frances, S. E., Edlund, P., Norberg, B., Wennstig, A.-K., Lind, P., Hauser, N., Tausch, C., Camci, C., Arpaci, F., Abali, H., Uslu, R., Tahir, S., Wheatley, D., Chan, S., Barrett-Lee, P., McAdam, K., Simcock, R., Burcombe, R., El-Maraghi, R., Califaretti, N., Spadafora, S., Sehdev, S., Sami, A., & Verma, S.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- European Institute of Oncology (IT)
- Sunnybrook Health Science Centre (CA)
- ORCID
- Jakobsen, Erik Hugger
- Bonnefoi, Herve
- Zelek, Laurent
- Bourgeois, Hugues
- Lefeuvre, Claudia Plesse
- Bachelot, Thomas
- Petit, Thierry
- Brain, Etienne
- Augustin, Doris
- Overkamp, Friedrich
- Schmidt, Marcus
- Colleoni, Marco
- Ballestrero, Alberto
- Gianni, Luca
- Jassem, Jacek
- Shirinkin, Vadim
- Manikhas, Alexey
- Bofill, Javier Salvador
- Wennstig, Anna-Karin
- Lind, Pehr
- Wheatley, Duncan
- Chan, Stephen
- Barrett-Lee, Peter
- McAdam, Karen
- Simcock, Richard
- Burcombe, Russell
- Califaretti, Nadia
- Spadafora, Silvana
- Sehdev, Sandeep
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 25
- Issue
- 10
- Pages
- 1979-1987
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W1549851394
- Cited by
- 177
- References
- 13
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 14 · 2023: 11 · 2022: 9 · 2021: 21 · 2020: 19 · 2019: 12 · 2018: 9 · 2017: 16 · 2016: 13 · 2015: 14 · 2014: 2
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1878 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- reroDoc Digital Library (submittedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- Funders
- F. Hoffmann-La Roche Ltd
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- subcutaneous trastuzumab, HER2-positive early breast cancer, adjuvant therapy, patient preferences, healthcare professional satisfaction, adverse events, drug delivery routes, patient-reported outcomes, safety and tolerability, patient-reported quality of life
- MeSH terms
- Trastuzumab, Adult, Aged, Breast Neoplasms, Female, Humans, Infusions, Intravenous, Injections, Subcutaneous, Male, Middle Aged, Cohort Studies, Treatment Outcome, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. https://app.cochat.ai/papers/10.1093/annonc/mdu364
- The paper
- Pivot, X., Gligorov, J., Müller, V., Curigliano, G., Knoop, A., Verma, S., Jenkins, V., Scotto, N., Osborne, S., Fallowfield, L., Fallowfield, L., Jenkins, V., Kilkerr, J., Langridge, C., Monson, K., Jakobsen, E. H., Nielsen, M. H., Linnet, S., Knoop, A., . . . Verma, S. (2014). Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Annals of Oncology. https://doi.org/10.1093/annonc/mdu364
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.